SCHEMBL1970585

SCHEMBL1970585

O=C(CCl)N(Cc1cccs1)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.64
▸ HTT P42858 3/20 0.64
▸ LMNA P02545 3/20 0.64
▸ NPC1 O15118 2/20 0.64
▸ RAB9A P51151 2/20 0.64
▸ MAPT P10636 2/20 0.64
▸ ATM Q13315 1/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ KMT2A Q03164 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ PKM P14618 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ TP53 P04637 5/20 0.45
▸ HPGD P15428 1/20 0.44
▸ JAK2 O60674 1/20 0.42
▸ PAX8 Q06710 1/20 0.42
▸ TRPM8 Q7Z2W7 1/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13120863 0.83 ALDH1A1 (0.49) ALDH1A1HTTLMNANPC1RAB9A
SCHEMBL8877711 0.73 ALDH1A1 (0.55) ALDH1A1HTTLMNANPC1RAB9A
SCHEMBL23818010 0.73 FNIP1 (0.58) ALDH1A1HTTLMNANPC1RAB9A
SCHEMBL25455117 0.69 CTNNB1 (0.48) ALDH1A1HTTLMNANPC1RAB9A
SCHEMBL1336792 0.69 ALDH1A1 (0.62) ALDH1A1HTTLMNANPC1RAB9A
SCHEMBL1336794 0.69 ALDH1A1 (0.62) ALDH1A1HTTLMNANPC1RAB9A
SCHEMBL15055794 0.67 ALDH1A1 (0.56) ALDH1A1HTTLMNARAB9AMAPT
SCHEMBL2720448 0.66 TRPM8 (0.60) LMNAMAPTPOLBTP53TRPM8
SCHEMBL4707186 0.66 TRPM8 (0.60) ALDH1A1HTTLMNANPC1RAB9A
SCHEMBL2419952 0.66 THRB (0.74) ALDH1A1HTTLMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334301-B1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK SERONO SA (CH) 2018-02-14 — — EP disclosed
US-8815872-B2 Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH (DE) 2014-08-26 — — US disclosed
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-12-01 — — US disclosed
CN-102143750-A Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH 2011-08-03 — — CN disclosed
EP-2334301-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS Merck Serono SA (CH) 2011-06-22 — — EP disclosed
WO-2010028116-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS AURKC, AURKA, AURKB ALDH1A1 4424/4885HTT 4089/4885LMNA 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback